EUVIMEDEUVIMED entdecken
Crossref

MicroNet Mesh-Covered Protection Stent for Carotid Artery Disease: Ten-Year Single-Center Experience

Edoardo Forcella, Davide Mastrorilli, Chiara De Massari, Tommaso Miccoli, Gianguido Pruner, Luca Garriboli

Annals of Vascular Surgery · 2026-07 · 128 · 329-337

DOI: 10.1016/j.avsg.2026.02.024 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Vascular Surgery, 2026-07. Verfasst von Edoardo Forcella und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Vascular Surgery, IRCCS Sacro Cuore Don Calabria, Negrar di Valpolicella, Verona, Italy. Electronic address: forcella.edoardo@gmail.com. Hauptthemen laut MEDLINE: Stents, Carotid Stenosis, Endovascular Procedures. Die Arbeit nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION This study evaluates the early and mid-term safety outcomes of CGuard carotid artery stenting (CAS) for asymptomatic carotid artery disease (CAD), with a focus on the accuracy of intra-operative stent release. METHODS We conducted a single-center retrospective study of patients undergoing CAS for asymptomatic carotid stenosis >70% (2015-2025) in a high-volume vascular. The primary endpoint was the perioperative rate of any death, stroke, or myocardial infarction. Secondary endpoints included technical success, the necessity for unplanned adjunctive carotid stenting, and operation time as indicators of the ease and accuracy of CGuard stent deployment. Freedom from restenosis and late neurological outcomes were also evaluated. Post-operative evaluations ensured alignment with pre-operative planning, verifying stent placement and appropriate lesion coverage. Kaplan Meier survival estimates of freedom from restenosis was assessed. RESULTS One-houndred-ten patients were included (male 73%). The 30-day clinical success rate was 100%, with no perioperative deaths, myocardial infarctions, or strokes. One patient experienced a transient ischemic attack. The mean operation time was 29 ± 8 minutes, and four patients (4%) required additional unplanned stenting. The median follow-up was 37 months, with an overall survival rate of 89% at 60 months. One case of stent stenosis occurred at 22 months, with a 60-month freedom from restenosis rate of 98% and primary-assisted patency of 100%. CONCLUSION Carotid artery stenting with the CGuard dual-layer stent was associated with high technical success, a low rate of early neurological events, and durable mid-term patency in asymptomatic patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

StentsCarotid StenosisEndovascular ProceduresHumansMaleRetrospective StudiesFemaleTime FactorsAgedProsthesis DesignRisk FactorsMiddle AgedTreatment OutcomeAged, 80 and overRecurrenceAsymptomatic DiseasesStroke

Autor:innen und Institutionen

  • Department of Vascular Surgery, IRCCS Sacro Cuore Don Calabria, Negrar di Valpolicella, Verona, Italy. Electronic address: forcella.edoardo@gmail.com.
  • Department of Vascular Surgery, IRCCS Sacro Cuore Don Calabria, Negrar di Valpolicella, Verona, Italy.

Zitieren

APA

Forcella, E., Mastrorilli, D., De Massari, C., Miccoli, T., Pruner, G., & Garriboli, L. (2026). MicroNet Mesh-Covered Protection Stent for Carotid Artery Disease: Ten-Year Single-Center Experience. Annals of Vascular Surgery, 128, 329-337. https://doi.org/10.1016/j.avsg.2026.02.024

Vancouver

Forcella E, Mastrorilli D, De Massari C, Miccoli T, Pruner G, Garriboli L. MicroNet Mesh-Covered Protection Stent for Carotid Artery Disease: Ten-Year Single-Center Experience. Annals of Vascular Surgery. 2026;128:329-337. doi:10.1016/j.avsg.2026.02.024

BibTeX
@article{Forcella2026,
  author = {Forcella, Edoardo and Mastrorilli, Davide and De Massari, Chiara and Miccoli, Tommaso and Pruner, Gianguido and Garriboli, Luca},
  title = {MicroNet Mesh-Covered Protection Stent for Carotid Artery Disease: Ten-Year Single-Center Experience},
  journal = {Annals of Vascular Surgery},
  year = {2026},
  volume = {128},
  pages = {329--337},
  doi = {10.1016/j.avsg.2026.02.024}
}
Kostenlos starten →